Circulating tumor necrosis factor α receptors predict the outcomes of human IgA nephropathy: A prospective cohort study

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Oh, Yun Jung ^a   An, Jung Nam ^b,c   Kim, Clara Tammy ^d   Yang, Seung Hee ^d   Lee, Hajeong ^c   Kim, Dong Ki ^c   Joo, Kwon Wook ^c   Paik, Jin Ho ^c   Kang, Shin Wook ^e   Park, Jung Tak ^e   Lim, Chun Soo ^b,c   Kim, Yon Su ^c   Lee, Jung Pyo ^b,c  

^a Department of Internal Medicine Cheju Halla General Hospital ^*  (South Korea)

^b Seoul National University Boramae Hospital   (South Korea)

^c Seoul National University College of Medicine   (South Korea)

^d Seoul National University   (South Korea)

^e Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BIOLOGICAL MARKER; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; FEMALE; FIBROSING ALVEOLITIS; GLOMERULUS FILTRATION RATE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY BIOPSY; KIDNEY FUNCTION; KIDNEY TUBULE DISORDER; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTION; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEINURIA; UNIVERSITY HOSPITAL; BLOOD; GLOMERULONEPHRITIS, IGA; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODEL; TREATMENT OUTCOME;

ADULT; BIOMARKERS; DISEASE PROGRESSION; FEMALE; GLOMERULONEPHRITIS, IGA; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; TREATMENT OUTCOME;

EID: 84941356114     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0132826     Document Type: Article

References (53)

1. Donadio JV, Grande JP. IgA nephropathy. N Engl J Med. 2002; 347: 738-748. PMID: 12213946
2. Chang JH, Kim DK, Kim HW, Park SY, Yoo TH, Kim BS, et al. Changing prevalence of glomerular diseases in Korean adults: a review of 20 years of experience. Nephrol Dial Transplant. 2009; 24: 2406-2410. doi: 10.1093/ndt/gfp091 PMID: 19264742
3. Radford MG Jr., Donadio JV Jr., Bergstralh EJ, Grande JP. Predicting renal outcome in IgA nephropathy. J Am Soc Nephrol. 1997; 8: 199-207. PMID: 9048338
4. Julian BA, Tomana M, Novak J, Mestecky J. Progress in the pathogenesis of IgA nephropathy. Adv Nephrol Necker Hosp. 1999; 29: 53-72. PMID: 10561737
5. Lee H, Kim DK, Oh KH, Joo KW, Kim YS, Chae DW, et al. Mortality of IgA Nephropathy Patients: A Single Center Experience over 30 Years. PLoS One. 2012; 7: e51225. doi: 10.1371/journal.pone. 0051225 PMID: 23226568
6. Beukhof JR, Kardaun O, Schaafsma W, Poortema K, Donker AJ, Hoedemaeker PJ, et al. Toward individual prognosis of IgA nephropathy. Kidney Int. 1986; 29: 549-556. PMID: 3702212
7. Xie J, Kiryluk K, Wang W, Wang Z, Guo S, Shen P, et al. Predicting progression of IgA nephropathy: new clinical progression risk score. PLoS One. 2012; 7: e38904. doi: 10.1371/journal.pone.0038904 PMID: 22719981
8. Alamartine E, Sabatier JC, Guerin C, Berliet JM, Berthoux F. Prognostic factors in mesangial IgA glomerulonephritis: an extensive study with univariate and multivariate analyses. Am J Kidney Dis. 1991; 18: 12-19. PMID: 2063844
9. Berthoux F, Mohey H, Laurent B, Mariat C, Afiani A, Thibaudin L. Predicting the risk for dialysis or death in IgA nephropathy. J Am Soc Nephrol. 2011; 22: 752-761. doi: 10.1681/ASN.2010040355 PMID: 21258035
10. Bartosik LP, Lajoie G, Sugar L, Cattran DC. Predicting progression in IgA nephropathy. Am J Kidney Dis. 2001; 38: 728-735. PMID: 11576875
11. Frimat L, Briancon S, Hestin D, Aymard B, Renoult E, Huu TC, et al. IgA nephropathy: prognostic classification of end-stage renal failure. L'Association des Nephrologues de l'Est. Nephrol Dial Transplant. 1997; 12: 2569-2575. PMID: 9430853
12. Richter C, Messerschmidt S, Holeiter G, Tepperink J, Osswald S, Zappe A, et al. The tumor necrosis factor receptor stalk regions define responsiveness to soluble versus membrane-bound ligand. Mol Cell Biol. 2012; 32: 2515-2529. doi: 10.1128/MCB.06458-11 PMID: 22547679
13. Bolton CH, Downs LG, Victory JG, Dwight JF, Tomson CR, Mackness MI, et al. Endothelial dysfunction in chronic renal failure: roles of lipoprotein oxidation and pro-inflammatory cytokines. Nephrol Dial Transplant. 2001; 16: 1189-1197. PMID: 11390719
14. Pereira BJ, Shapiro L, King AJ, Falagas ME, Strom JA, Dinarello CA. Plasma levels of IL-1 beta, TNF alpha and their specific inhibitors in undialyzed chronic renal failure, CAPD and hemodialysis patients. Kidney Int. 1994; 45: 890-896. PMID: 8196293
15. Knight EL, Rimm EB, Pai JK, Rexrode KM, Cannuscio CC, Manson JE, et al. Kidney dysfunction, inflammation, and coronary events: a prospective study. J Am Soc Nephrol. 2004; 15: 1897-1903. PMID: 15213279
16. Hasegawa M, Nishii C, Ohashi A, Tomita M, Nakai S, Murakami K, et al. Expression of tumor necrosis factor receptors on granulocytes in patients with myeloperoxidase anti-neutrophil cytoplasmic autoantibody-Associated vasculitis. Nephron Clin Pract. 2009; 113: c222-233. doi: 10.1159/000235242 PMID: 19690440
17. Speeckaert MM, Speeckaert R, Laute M, Vanholder R, Delanghe JR. Tumor necrosis factor receptors: biology and therapeutic potential in kidney diseases. Am J Nephrol. 2012; 36: 261-270. doi: 10.1159/000342333 PMID: 22965073
18. Gohda T, Niewczas MA, Ficociello LH, Walker WH, Skupien J, Rosetti F, et al. Circulating TNF Receptors 1 and 2 Predict Stage 3 CKD in Type 1 Diabetes. J Am Soc Nephrol. 2012; 23: 516-524. doi: 10. 1681/ASN.2011060628 PMID: 22266664
19. Niewczas MA, Gohda T, Skupien J, Smiles AM, Walker WH, Rosetti F. Circulating TNF Receptors 1 and 2 Predict ESRD in Type 2 Diabetes. J Am Soc Nephrol. 2012; 23: 507-515. doi: 10.1681/ASN. 2011060627 PMID: 22266663
20. Zhu L, Yang X, Ji Y, Chen W, Guan W, Zhou SF, et al. Up-regulated renal expression of TNF-Alpha signalling adapter proteins in lupus glomerulonephritis. Lupus. 2009; 18: 116-127. doi: 10.1177/0961203308094764 PMID: 19151112
21. Wu T, Xie C, Wang HW, Zhou XJ, Schwartz N, Calixto S, et al. Elevated urinary VCAM-1, P-selectin, soluble TNF receptor-1, and CXC chemokine ligand 16 in multiple murine lupus strains and human lupus nephritis. J Immunol. 2007; 179: 7166-7175. PMID: 17982109
22. Idasiak-Piechocka I, Oko A, Pawliczak E, Kaczmarek E, Czekalski S. Urinary excretion of soluble tumour necrosis factor receptor 1 as a marker of increased risk of progressive kidney function deterioration in patients with primary chronic glomerulonephritis. Nephrol Dial Transplant. 2010; 25: 3948-3956. doi: 10.1093/ndt/gfq310 PMID: 20525973
23. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006; 145: 247-254. PMID: 16908915
24. Lee HS, Lee MS, Lee SM, Lee SY, Lee ES, Lee EY, et al. Histological grading of IgA nephropathy predicting renal outcome: revisiting H. S. Lee's glomerular grading system. Nephrol Dial Transplant. 2005; 20: 342-348. PMID: 15618239
25. Lee JP, Yang SH, Kim DK, Lee H, Kim B, Cho JY, et al. In vivo activity of epoxide hydrolase according to sequence variation affects the progression of human IgA nephropathy. Am J Physiol Renal Physiol. 2011; 300: F1283-1290. doi: 10.1152/ajprenal.00733.2010 PMID: 21429967
26. Niewczas MA, Ficociello LH, Johnson AC, Walker W, Rosolowsky ET, Roshan B, et al. Serum concentrations of markers of TNFalpha and Fas-mediated pathways and renal function in nonproteinuric patients with type 1 diabetes. Clin J Am Soc Nephrol. 2009; 4: 62-70. doi: 10.2215/CJN.03010608 PMID: 19073786
27. Carlsson AC, Larsson TE, Helmersson-Karlqvist J, Larsson A, Lind L, Arnlöv J. Soluble TNF Receptors and Kidney Dysfunction in the Elderly. Journal of the American Society of Nephrology. 2014; 25: 1313-1320. doi: 10.1681/ASN.2013080860 PMID: 24511129
28. Lopes-Virella MF, Baker NL, Hunt KJ, Cleary PA, Klein R, Virella G. Baseline markers of inflammation are associated with progression to macroalbuminuria in type 1 diabetic subjects. Diabetes Care. 2013; 36: 2317-2323. doi: 10.2337/dc12-2521 PMID: 23514730
29. Krolewski AS, Niewczas MA, Skupien J, Gohda T, Smiles A, Eckfeldt JH, et al. Early progressive renal decline precedes the onset of microalbuminuria and its progression to macroalbuminuria. Diabetes Care. 2014; 37: 226-234. doi: 10.2337/dc13-0985 PMID: 23939543
30. Miyazawa I, Araki S, Obata T, Yoshizaki T, Morino K, Kadota A, et al. Association between serum soluble TNFalpha receptors and renal dysfunction in type 2 diabetic patients without proteinuria. Diabetes Res Clin Pract. 2011; 92: 174-180. doi: 10.1016/j.diabres.2011.01.008 PMID: 21288590
31. Upadhyay A, Larson MG, Guo CY, Vasan RS, Lipinska I, O'Donnell CJ, et al. Inflammation, kidney function and albuminuria in the Framingham Offspring cohort. Nephrol Dial Transplant. 2011; 26: 920-926. doi: 10.1093/ndt/gfq471 PMID: 20682604
32. Keller C, Katz R, Cushman M, Fried LF, Shlipak M. Association of kidney function with inflammatory and procoagulant markers in a diverse cohort: a cross-sectional analysis from the Multi-Ethnic Study of Atherosclerosis (MESA). BMC Nephrol. 2008; 9: 9. doi: 10.1186/1471-2369-9-9 PMID: 18681974
33. Lee SM, Yang S, Cha RH, Kim M, An JN, Paik JH, et al. Circulating TNF receptors are significant prognostic biomarkers for idiopathic membranous nephropathy. PLoS One. 2014; 9: e104354. doi: 10. 1371/journal.pone.0104354 PMID: 25098821
34. Chan LY, Leung JC, Tsang AW, Tang SC, Lai KN. Activation of tubular epithelial cells by mesangialderived TNF-Alpha: glomerulotubular communication in IgA nephropathy. Kidney Int. 2005; 67: 602-612. PMID: 15673307
35. Lai KN, Leung JC, Chan LY, Saleem MA, Mathieson PW, Lai FM, et al. Activation of podocytes by mesangial-derived TNF-Alpha: glomerulo-podocytic communication in IgA nephropathy. Am J Physiol Renal Physiol. 2008; 294: F945-955. doi: 10.1152/ajprenal.00423.2007 PMID: 18256312
36. Guo G, Morrissey J, McCracken R, Tolley T, Klahr S. Role of TNFR1 and TNFR2 receptors in tubulointerstitial fibrosis of obstructive nephropathy. Am J Physiol. 1999; 277: F766-772. PMID: 10564241
37. Al-Lamki RS, Wang J, Vandenabeele P, Bradley JA, Thiru S, Luo D, et al. TNFR1-And TNFR2-mediated signaling pathways in human kidney are cell type-specific and differentially contribute to renal injury. FASEB J. 2005; 19: 1637-1645. PMID: 16195372
38. Sonoda Y, Gohda T, Suzuki Y, Omote K, Ishizaka M, Matsuoka J, et al. Circulating TNF receptors 1 and 2 are associated with the severity of renal interstitial fibrosis in IgA nephropathy. PLoS One. 2015; 10: e0122212. doi: 10.1371/journal.pone.0122212 PMID: 25860248
39. Al-Lamki RS, Wang J, Skepper JN, Thiru S, Pober JS, Bradley JR. Expression of tumor necrosis factor receptors in normal kidney and rejecting renal transplants. Lab Invest. 2001; 81: 1503-1515. PMID: 11706058
40. Kollias G, Kontoyiannis D. Role of TNF/TNFR in autoimmunity: specific TNF receptor blockade may be advantageous to anti-TNF treatments. Cytokine Growth Factor Rev. 2002; 13: 315-321. PMID: 12220546
41. Pfeffer K. Biological functions of tumor necrosis factor cytokines and their receptors. Cytokine Growth Factor Rev. 2003; 14: 185-191. PMID: 12787558
42. Grell M, Becke FM, Wajant H, Mannel DN, Scheurich P. TNF receptor type 2 mediates thymocyte proliferation independently of TNF receptor type 1. Eur J Immunol. 1998; 28: 257-263. PMID: 9485205
43. Bertani T, Abbate M, Zoja C, Corna D, Perico N, Ghezzi P, et al. Tumor necrosis factor induces glomerular damage in the rabbit. The American journal of pathology. 1989; 134: 419-430. PMID: 2916653
44. Tomosugi NI, Cashman SJ, Hay H, Pusey CD, Evans DJ, Shaw A, et al. Modulation of antibody-mediated glomerular injury in vivo by bacterial lipopolysaccharide, tumor necrosis factor, and IL-1. J Immunol. 1989; 142: 3083-3090. PMID: 2785133
45. Neale TJ, Ruger BM, Macaulay H, Dunbar PR, Hasan Q, Bourke A, et al. Tumor necrosis factor-Alpha is expressed by glomerular visceral epithelial cells in human membranous nephropathy. The American journal of pathology. 1995; 146: 1444-1454. PMID: 7778683
46. Karkar AM, Smith J, Pusey CD. Prevention and treatment of experimental crescentic glomerulonephritis by blocking tumour necrosis factor-Alpha. Nephrol Dial Transplant. 2001; 16: 518-524. PMID: 11239025
47. Vielhauer V, Stavrakis G, Mayadas TN. Renal cell-expressed TNF receptor 2, not receptor 1, is essential for the development of glomerulonephritis. J Clin Invest. 2005; 115: 1199-1209. PMID: 15841213
48. Feldmann M, Pusey CD. Is there a role for TNF-Alpha in anti-neutrophil cytoplasmic antibody-Associated vasculitis? Lessons from other chronic inflammatory diseases. J Am Soc Nephrol. 2006; 17: 1243-1252. PMID: 16624928
49. Khan SB, Cook HT, Bhangal G, Smith J, Tam FW, Pusey CD. Antibody blockade of TNF-Alpha reduces inflammation and scarring in experimental crescentic glomerulonephritis. Kidney Int. 2005; 67: 1812-1820. PMID: 15840028
50. Ernandez T, Mayadas TN. Immunoregulatory role of TNFalpha in inflammatory kidney diseases. Kidney Int. 2009; 76: 262-276. doi: 10.1038/ki.2009.142 PMID: 19436333
51. Nicholls KM, Fairley KF, Dowling JP, Kincaid-Smith P. The clinical course of mesangial IgA associated nephropathy in adults. Q J Med. 1984; 53: 227-250. PMID: 6463197
52. D'Amico G, Ferrario F, Rastaldi MP. Tubulointerstitial damage in glomerular diseases: its role in the progression of renal damage. Am J Kidney Dis. 1995; 26: 124-132. PMID: 7611242
53. Wu T, Xie C, Bhaskarabhatla M, Yan M, Leone A, Chen SS, et al. Excreted urinary mediators in an animal model of experimental immune nephritis with potential pathogenic significance. Arthritis Rheum. 2007; 56: 949-959. PMID: 17328072